nodes	percent_of_prediction	percent_of_DWPC	metapath
Ingenol Mebutate—PRKCA—cerebellar cortex—epilepsy syndrome	0.0481	0.223	CbGeAlD
Ingenol Mebutate—PRKCA—telencephalic ventricle—epilepsy syndrome	0.028	0.13	CbGeAlD
Ingenol Mebutate—PRKCA—ganglion—epilepsy syndrome	0.0174	0.0806	CbGeAlD
Ingenol Mebutate—PRKCD—forebrain—epilepsy syndrome	0.0133	0.0614	CbGeAlD
Ingenol Mebutate—PRKCA—hindbrain—epilepsy syndrome	0.0132	0.0612	CbGeAlD
Ingenol Mebutate—PRKCD—telencephalon—epilepsy syndrome	0.0122	0.0564	CbGeAlD
Ingenol Mebutate—Instillation site pain—Midazolam—epilepsy syndrome	0.0101	0.0461	CcSEcCtD
Ingenol Mebutate—PRKCD—head—epilepsy syndrome	0.0076	0.0351	CbGeAlD
Ingenol Mebutate—PRKCA—brainstem—epilepsy syndrome	0.00758	0.0351	CbGeAlD
Ingenol Mebutate—Application site pain—Midazolam—epilepsy syndrome	0.00752	0.0342	CcSEcCtD
Ingenol Mebutate—PRKCA—forebrain—epilepsy syndrome	0.00731	0.0338	CbGeAlD
Ingenol Mebutate—PRKCD—nervous system—epilepsy syndrome	0.0072	0.0333	CbGeAlD
Ingenol Mebutate—Periorbital oedema—Clonazepam—epilepsy syndrome	0.00699	0.0318	CcSEcCtD
Ingenol Mebutate—PRKCD—central nervous system—epilepsy syndrome	0.00693	0.0321	CbGeAlD
Ingenol Mebutate—PRKCD—cerebellum—epilepsy syndrome	0.00678	0.0313	CbGeAlD
Ingenol Mebutate—PRKCA—telencephalon—epilepsy syndrome	0.00673	0.0311	CbGeAlD
Ingenol Mebutate—PRKCD—brain—epilepsy syndrome	0.0055	0.0255	CbGeAlD
Ingenol Mebutate—PRKCA—midbrain—epilepsy syndrome	0.00483	0.0223	CbGeAlD
Ingenol Mebutate—PRKCA—spinal cord—epilepsy syndrome	0.00471	0.0218	CbGeAlD
Ingenol Mebutate—PRKCA—head—epilepsy syndrome	0.00419	0.0194	CbGeAlD
Ingenol Mebutate—PRKCA—nervous system—epilepsy syndrome	0.00397	0.0184	CbGeAlD
Ingenol Mebutate—PRKCA—central nervous system—epilepsy syndrome	0.00382	0.0177	CbGeAlD
Ingenol Mebutate—PRKCA—cerebellum—epilepsy syndrome	0.00374	0.0173	CbGeAlD
Ingenol Mebutate—Eyelid oedema—Pregabalin—epilepsy syndrome	0.0036	0.0164	CcSEcCtD
Ingenol Mebutate—Periorbital oedema—Topiramate—epilepsy syndrome	0.00355	0.0161	CcSEcCtD
Ingenol Mebutate—PRKCA—brain—epilepsy syndrome	0.00303	0.014	CbGeAlD
Ingenol Mebutate—Nasopharyngitis—Rufinamide—epilepsy syndrome	0.00291	0.0132	CcSEcCtD
Ingenol Mebutate—Eyelid oedema—Topiramate—epilepsy syndrome	0.00278	0.0126	CcSEcCtD
Ingenol Mebutate—Eye disorder—Primidone—epilepsy syndrome	0.00275	0.0125	CcSEcCtD
Ingenol Mebutate—Swelling—Midazolam—epilepsy syndrome	0.00272	0.0124	CcSEcCtD
Ingenol Mebutate—Eye pain—Propofol—epilepsy syndrome	0.00272	0.0124	CcSEcCtD
Ingenol Mebutate—Eye pain—Fosphenytoin—epilepsy syndrome	0.00253	0.0115	CcSEcCtD
Ingenol Mebutate—Infestation—Rufinamide—epilepsy syndrome	0.00251	0.0114	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Rufinamide—epilepsy syndrome	0.00251	0.0114	CcSEcCtD
Ingenol Mebutate—Swelling—Diazepam—epilepsy syndrome	0.00249	0.0113	CcSEcCtD
Ingenol Mebutate—Eye pain—Vigabatrin—epilepsy syndrome	0.00247	0.0112	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Clobazam—epilepsy syndrome	0.00228	0.0104	CcSEcCtD
Ingenol Mebutate—Infestation—Clobazam—epilepsy syndrome	0.00228	0.0104	CcSEcCtD
Ingenol Mebutate—Swelling—Clonazepam—epilepsy syndrome	0.00227	0.0103	CcSEcCtD
Ingenol Mebutate—Eye pain—Phenytoin—epilepsy syndrome	0.00221	0.01	CcSEcCtD
Ingenol Mebutate—Swelling—Carbamazepine—epilepsy syndrome	0.00216	0.00979	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Midazolam—epilepsy syndrome	0.00215	0.00976	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Levetiracetam—epilepsy syndrome	0.00212	0.00964	CcSEcCtD
Ingenol Mebutate—Eye disorder—Rufinamide—epilepsy syndrome	0.0021	0.00956	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Primidone—epilepsy syndrome	0.00205	0.00932	CcSEcCtD
Ingenol Mebutate—Eye pain—Lamotrigine—epilepsy syndrome	0.00204	0.00925	CcSEcCtD
Ingenol Mebutate—Erythema—Phenobarbital—epilepsy syndrome	0.002	0.00907	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Vigabatrin—epilepsy syndrome	0.00199	0.00906	CcSEcCtD
Ingenol Mebutate—Eye disorder—Lacosamide—epilepsy syndrome	0.00197	0.00897	CcSEcCtD
Ingenol Mebutate—Eye disorder—Clobazam—epilepsy syndrome	0.00192	0.00871	CcSEcCtD
Ingenol Mebutate—Erythema—Lacosamide—epilepsy syndrome	0.00184	0.00836	CcSEcCtD
Ingenol Mebutate—Infestation—Levetiracetam—epilepsy syndrome	0.00183	0.0083	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Levetiracetam—epilepsy syndrome	0.00183	0.0083	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Clonazepam—epilepsy syndrome	0.00179	0.00815	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Levetiracetam—epilepsy syndrome	0.00178	0.00807	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Oxcarbazepine—epilepsy syndrome	0.00177	0.00805	CcSEcCtD
Ingenol Mebutate—Infestation—Vigabatrin—epilepsy syndrome	0.00172	0.00781	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Vigabatrin—epilepsy syndrome	0.00172	0.00781	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Fosphenytoin—epilepsy syndrome	0.00171	0.00779	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Vigabatrin—epilepsy syndrome	0.00167	0.00759	CcSEcCtD
Ingenol Mebutate—Swelling—Valproic Acid—epilepsy syndrome	0.00166	0.00752	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Diazepam—epilepsy syndrome	0.00165	0.00748	CcSEcCtD
Ingenol Mebutate—Eye pain—Valproic Acid—epilepsy syndrome	0.00162	0.00735	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Felbamate—epilepsy syndrome	0.00159	0.00724	CcSEcCtD
Ingenol Mebutate—Infection—Rufinamide—epilepsy syndrome	0.00159	0.00722	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Rufinamide—epilepsy syndrome	0.00157	0.00713	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Zonisamide—epilepsy syndrome	0.00156	0.00708	CcSEcCtD
Ingenol Mebutate—Eye disorder—Midazolam—epilepsy syndrome	0.00155	0.00705	CcSEcCtD
Ingenol Mebutate—Eye disorder—Levetiracetam—epilepsy syndrome	0.00153	0.00697	CcSEcCtD
Ingenol Mebutate—Infestation—Oxcarbazepine—epilepsy syndrome	0.00153	0.00694	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Oxcarbazepine—epilepsy syndrome	0.00153	0.00694	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Phenytoin—epilepsy syndrome	0.00149	0.00678	CcSEcCtD
Ingenol Mebutate—Erythema—Propofol—epilepsy syndrome	0.00148	0.00672	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Lacosamide—epilepsy syndrome	0.00147	0.00669	CcSEcCtD
Ingenol Mebutate—Infestation—Carbamazepine—epilepsy syndrome	0.00147	0.00666	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Carbamazepine—epilepsy syndrome	0.00147	0.00666	CcSEcCtD
Ingenol Mebutate—Eye pain—Pregabalin—epilepsy syndrome	0.00146	0.00664	CcSEcCtD
Ingenol Mebutate—Infection—Clobazam—epilepsy syndrome	0.00145	0.00658	CcSEcCtD
Ingenol Mebutate—Erythema—Midazolam—epilepsy syndrome	0.00145	0.00657	CcSEcCtD
Ingenol Mebutate—Eye disorder—Vigabatrin—epilepsy syndrome	0.00144	0.00655	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Clobazam—epilepsy syndrome	0.00143	0.00649	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Carbamazepine—epilepsy syndrome	0.00142	0.00647	CcSEcCtD
Ingenol Mebutate—Eye disorder—Diazepam—epilepsy syndrome	0.00142	0.00645	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Lamotrigine—epilepsy syndrome	0.00142	0.00643	CcSEcCtD
Ingenol Mebutate—Infestation—Lamotrigine—epilepsy syndrome	0.00142	0.00643	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Lamotrigine—epilepsy syndrome	0.00138	0.00625	CcSEcCtD
Ingenol Mebutate—Swelling—Gabapentin—epilepsy syndrome	0.00137	0.00624	CcSEcCtD
Ingenol Mebutate—Headache—Amobarbital—epilepsy syndrome	0.00136	0.00618	CcSEcCtD
Ingenol Mebutate—Eye disorder—Zonisamide—epilepsy syndrome	0.00135	0.00611	CcSEcCtD
Ingenol Mebutate—Eye pain—Gabapentin—epilepsy syndrome	0.00134	0.00609	CcSEcCtD
Ingenol Mebutate—Erythema—Diazepam—epilepsy syndrome	0.00132	0.00601	CcSEcCtD
Ingenol Mebutate—Headache—Primidone—epilepsy syndrome	0.00131	0.00595	CcSEcCtD
Ingenol Mebutate—Eye disorder—Clonazepam—epilepsy syndrome	0.0013	0.00589	CcSEcCtD
Ingenol Mebutate—Eye disorder—Oxcarbazepine—epilepsy syndrome	0.00128	0.00582	CcSEcCtD
Ingenol Mebutate—Eye disorder—Carbamazepine—epilepsy syndrome	0.00123	0.00559	CcSEcCtD
Ingenol Mebutate—Eye disorder—Lamotrigine—epilepsy syndrome	0.00119	0.0054	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Pregabalin—epilepsy syndrome	0.00118	0.00536	CcSEcCtD
Ingenol Mebutate—Infection—Levetiracetam—epilepsy syndrome	0.00116	0.00526	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Midazolam—epilepsy syndrome	0.00116	0.00526	CcSEcCtD
Ingenol Mebutate—Headache—Trimethadione—epilepsy syndrome	0.00115	0.00524	CcSEcCtD
Ingenol Mebutate—Erythema—Carbamazepine—epilepsy syndrome	0.00114	0.0052	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Levetiracetam—epilepsy syndrome	0.00114	0.00519	CcSEcCtD
Ingenol Mebutate—Eye pain—Topiramate—epilepsy syndrome	0.00113	0.00513	CcSEcCtD
Ingenol Mebutate—Infection—Fosphenytoin—epilepsy syndrome	0.00112	0.00508	CcSEcCtD
Ingenol Mebutate—Erythema—Lamotrigine—epilepsy syndrome	0.00111	0.00503	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Valproic Acid—epilepsy syndrome	0.00109	0.00497	CcSEcCtD
Ingenol Mebutate—Infection—Vigabatrin—epilepsy syndrome	0.00109	0.00495	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Gabapentin—epilepsy syndrome	0.00108	0.00492	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Vigabatrin—epilepsy syndrome	0.00108	0.00489	CcSEcCtD
Ingenol Mebutate—Infection—Diazepam—epilepsy syndrome	0.00107	0.00487	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Diazepam—epilepsy syndrome	0.00106	0.00481	CcSEcCtD
Ingenol Mebutate—Infection—Felbamate—epilepsy syndrome	0.00104	0.00472	CcSEcCtD
Ingenol Mebutate—Headache—Phenobarbital—epilepsy syndrome	0.00102	0.00464	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Pregabalin—epilepsy syndrome	0.00102	0.00462	CcSEcCtD
Ingenol Mebutate—Infestation—Pregabalin—epilepsy syndrome	0.00102	0.00462	CcSEcCtD
Ingenol Mebutate—Infection—Zonisamide—epilepsy syndrome	0.00102	0.00462	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Zonisamide—epilepsy syndrome	0.001	0.00456	CcSEcCtD
Ingenol Mebutate—Headache—Rufinamide—epilepsy syndrome	0.001	0.00455	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Pregabalin—epilepsy syndrome	0.000989	0.00449	CcSEcCtD
Ingenol Mebutate—Infection—Clonazepam—epilepsy syndrome	0.000979	0.00445	CcSEcCtD
Ingenol Mebutate—Infection—Phenytoin—epilepsy syndrome	0.000973	0.00442	CcSEcCtD
Ingenol Mebutate—Infection—Oxcarbazepine—epilepsy syndrome	0.000967	0.0044	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Clonazepam—epilepsy syndrome	0.000966	0.00439	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Phenytoin—epilepsy syndrome	0.00096	0.00436	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Oxcarbazepine—epilepsy syndrome	0.000955	0.00434	CcSEcCtD
Ingenol Mebutate—Eye disorder—Valproic Acid—epilepsy syndrome	0.000944	0.00429	CcSEcCtD
Ingenol Mebutate—Headache—Lacosamide—epilepsy syndrome	0.00094	0.00427	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Gabapentin—epilepsy syndrome	0.000933	0.00424	CcSEcCtD
Ingenol Mebutate—Infestation—Gabapentin—epilepsy syndrome	0.000933	0.00424	CcSEcCtD
Ingenol Mebutate—Infection—Carbamazepine—epilepsy syndrome	0.000928	0.00422	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Carbamazepine—epilepsy syndrome	0.000916	0.00416	CcSEcCtD
Ingenol Mebutate—Headache—Clobazam—epilepsy syndrome	0.000913	0.00415	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Topiramate—epilepsy syndrome	0.000911	0.00414	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Gabapentin—epilepsy syndrome	0.000907	0.00412	CcSEcCtD
Ingenol Mebutate—Infection—Lamotrigine—epilepsy syndrome	0.000897	0.00408	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Lamotrigine—epilepsy syndrome	0.000886	0.00402	CcSEcCtD
Ingenol Mebutate—Eye disorder—Pregabalin—epilepsy syndrome	0.000853	0.00388	CcSEcCtD
Ingenol Mebutate—Headache—Acetazolamide—epilepsy syndrome	0.000814	0.0037	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Topiramate—epilepsy syndrome	0.000785	0.00357	CcSEcCtD
Ingenol Mebutate—Infestation—Topiramate—epilepsy syndrome	0.000785	0.00357	CcSEcCtD
Ingenol Mebutate—Eye disorder—Gabapentin—epilepsy syndrome	0.000783	0.00356	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Topiramate—epilepsy syndrome	0.000763	0.00347	CcSEcCtD
Ingenol Mebutate—Headache—Propofol—epilepsy syndrome	0.000756	0.00343	CcSEcCtD
Ingenol Mebutate—Headache—Midazolam—epilepsy syndrome	0.000739	0.00336	CcSEcCtD
Ingenol Mebutate—Headache—Levetiracetam—epilepsy syndrome	0.00073	0.00332	CcSEcCtD
Ingenol Mebutate—Erythema—Gabapentin—epilepsy syndrome	0.000729	0.00331	CcSEcCtD
Ingenol Mebutate—Infection—Valproic Acid—epilepsy syndrome	0.000713	0.00324	CcSEcCtD
Ingenol Mebutate—Headache—Fosphenytoin—epilepsy syndrome	0.000705	0.0032	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.000704	0.0032	CcSEcCtD
Ingenol Mebutate—Headache—Vigabatrin—epilepsy syndrome	0.000687	0.00312	CcSEcCtD
Ingenol Mebutate—Headache—Diazepam—epilepsy syndrome	0.000676	0.00307	CcSEcCtD
Ingenol Mebutate—Eye disorder—Topiramate—epilepsy syndrome	0.000658	0.00299	CcSEcCtD
Ingenol Mebutate—Headache—Felbamate—epilepsy syndrome	0.000654	0.00297	CcSEcCtD
Ingenol Mebutate—Infection—Pregabalin—epilepsy syndrome	0.000645	0.00293	CcSEcCtD
Ingenol Mebutate—Headache—Zonisamide—epilepsy syndrome	0.000641	0.00291	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000636	0.00289	CcSEcCtD
Ingenol Mebutate—Headache—Clonazepam—epilepsy syndrome	0.000617	0.00281	CcSEcCtD
Ingenol Mebutate—Headache—Phenytoin—epilepsy syndrome	0.000613	0.00279	CcSEcCtD
Ingenol Mebutate—Erythema—Topiramate—epilepsy syndrome	0.000613	0.00279	CcSEcCtD
Ingenol Mebutate—Headache—Oxcarbazepine—epilepsy syndrome	0.00061	0.00277	CcSEcCtD
Ingenol Mebutate—Infection—Gabapentin—epilepsy syndrome	0.000591	0.00269	CcSEcCtD
Ingenol Mebutate—Headache—Carbamazepine—epilepsy syndrome	0.000585	0.00266	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000583	0.00265	CcSEcCtD
Ingenol Mebutate—Headache—Lamotrigine—epilepsy syndrome	0.000566	0.00257	CcSEcCtD
Ingenol Mebutate—Infection—Topiramate—epilepsy syndrome	0.000497	0.00226	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Topiramate—epilepsy syndrome	0.000491	0.00223	CcSEcCtD
Ingenol Mebutate—Headache—Valproic Acid—epilepsy syndrome	0.00045	0.00204	CcSEcCtD
Ingenol Mebutate—Headache—Pregabalin—epilepsy syndrome	0.000406	0.00185	CcSEcCtD
Ingenol Mebutate—Headache—Gabapentin—epilepsy syndrome	0.000373	0.00169	CcSEcCtD
Ingenol Mebutate—Headache—Topiramate—epilepsy syndrome	0.000314	0.00142	CcSEcCtD
Ingenol Mebutate—PRKCA—Signaling by NGF—SRC—epilepsy syndrome	4.43e-05	7.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—SRC—epilepsy syndrome	4.4e-05	7.81e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Insulin Signaling—AKT1—epilepsy syndrome	4.38e-05	7.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—AKT3—epilepsy syndrome	4.38e-05	7.77e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—TSC2—epilepsy syndrome	4.37e-05	7.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—PRKCB—epilepsy syndrome	4.36e-05	7.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signal transduction—AKT1—epilepsy syndrome	4.36e-05	7.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—POMC—epilepsy syndrome	4.35e-05	7.72e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—IL6ST—epilepsy syndrome	4.35e-05	7.71e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR—AKT1—epilepsy syndrome	4.34e-05	7.7e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—EGF/EGFR Signaling Pathway—AKT1—epilepsy syndrome	4.34e-05	7.7e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—HBEGF—epilepsy syndrome	4.34e-05	7.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by ERBB2—AKT1—epilepsy syndrome	4.32e-05	7.66e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 signaling—AKT1—epilepsy syndrome	4.3e-05	7.62e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—IL6ST—epilepsy syndrome	4.29e-05	7.6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—CDC42—epilepsy syndrome	4.28e-05	7.59e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—GFAP—epilepsy syndrome	4.28e-05	7.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—GAL—epilepsy syndrome	4.28e-05	7.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—ADAM10—epilepsy syndrome	4.28e-05	7.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—APOE—epilepsy syndrome	4.27e-05	7.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—AKT3—epilepsy syndrome	4.26e-05	7.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—CCL2—epilepsy syndrome	4.26e-05	7.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CHRM3—epilepsy syndrome	4.23e-05	7.5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—GRM5—epilepsy syndrome	4.23e-05	7.5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CASP2—epilepsy syndrome	4.23e-05	7.5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CD40—epilepsy syndrome	4.21e-05	7.47e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—JUNB—epilepsy syndrome	4.16e-05	7.38e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—AVP—epilepsy syndrome	4.14e-05	7.34e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ABCG2—epilepsy syndrome	4.12e-05	7.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CX3CR1—epilepsy syndrome	4.05e-05	7.19e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 interactions—AKT1—epilepsy syndrome	4.04e-05	7.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR in disease—AKT1—epilepsy syndrome	4.04e-05	7.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—S100B—epilepsy syndrome	4.04e-05	7.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—CYP2C19—epilepsy syndrome	4.02e-05	7.13e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—IL6ST—epilepsy syndrome	4.01e-05	7.12e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR—AKT1—epilepsy syndrome	4.01e-05	7.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—SOCS3—epilepsy syndrome	4e-05	7.1e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CDC42—epilepsy syndrome	3.99e-05	7.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—CYP11A1—epilepsy syndrome	3.99e-05	7.08e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—FOS—epilepsy syndrome	3.98e-05	7.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—NOS2—epilepsy syndrome	3.98e-05	7.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CHRM2—epilepsy syndrome	3.98e-05	7.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—BDKRB1—epilepsy syndrome	3.98e-05	7.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CX3CL1—epilepsy syndrome	3.98e-05	7.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR in Cancer—AKT1—epilepsy syndrome	3.97e-05	7.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—ALB—epilepsy syndrome	3.97e-05	7.04e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—HBEGF—epilepsy syndrome	3.96e-05	7.03e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by PDGF—AKT1—epilepsy syndrome	3.95e-05	7.02e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—FOS—epilepsy syndrome	3.93e-05	6.96e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—SLC2A1—epilepsy syndrome	3.89e-05	6.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—AKT3—epilepsy syndrome	3.89e-05	6.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—CASP8—epilepsy syndrome	3.89e-05	6.9e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—CDC42—epilepsy syndrome	3.88e-05	6.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—GABBR1—epilepsy syndrome	3.87e-05	6.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—AVP—epilepsy syndrome	3.87e-05	6.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—JUNB—epilepsy syndrome	3.86e-05	6.85e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—CASP8—epilepsy syndrome	3.84e-05	6.8e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—NOS1—epilepsy syndrome	3.83e-05	6.8e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	3.81e-05	6.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—AVP—epilepsy syndrome	3.76e-05	6.67e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HRH3—epilepsy syndrome	3.71e-05	6.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—HBEGF—epilepsy syndrome	3.66e-05	6.49e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—HES1—epilepsy syndrome	3.66e-05	6.49e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—OPRM1—epilepsy syndrome	3.65e-05	6.47e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—CYP2D6—epilepsy syndrome	3.6e-05	6.39e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—S100B—epilepsy syndrome	3.59e-05	6.37e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—AKT3—epilepsy syndrome	3.59e-05	6.37e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—NGF signalling via TRKA from the plasma membrane—AKT1—epilepsy syndrome	3.58e-05	6.35e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—SOCS3—epilepsy syndrome	3.56e-05	6.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—FYN—epilepsy syndrome	3.56e-05	6.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CDC42—epilepsy syndrome	3.55e-05	6.29e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—H2AFX—epilepsy syndrome	3.54e-05	6.28e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MEF2C—epilepsy syndrome	3.54e-05	6.27e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—CCR5—epilepsy syndrome	3.52e-05	6.24e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—FGF2—epilepsy syndrome	3.51e-05	6.23e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—ADAM10—epilepsy syndrome	3.51e-05	6.22e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—FGF2—epilepsy syndrome	3.47e-05	6.15e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CCR3—epilepsy syndrome	3.45e-05	6.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—HTR2A—epilepsy syndrome	3.45e-05	6.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ADRA2A—epilepsy syndrome	3.43e-05	6.08e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—YWHAZ—epilepsy syndrome	3.42e-05	6.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—BCHE—epilepsy syndrome	3.42e-05	6.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism of mRNA—AKT1—epilepsy syndrome	3.41e-05	6.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	3.39e-05	6.01e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—NGF—epilepsy syndrome	3.38e-05	6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—NPY—epilepsy syndrome	3.36e-05	5.96e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—ATP2A2—epilepsy syndrome	3.36e-05	5.96e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—SIRT1—epilepsy syndrome	3.35e-05	5.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—BCL2—epilepsy syndrome	3.34e-05	5.92e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—VDR—epilepsy syndrome	3.3e-05	5.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—BCL2—epilepsy syndrome	3.29e-05	5.84e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CCR5—epilepsy syndrome	3.29e-05	5.83e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CDC42—epilepsy syndrome	3.28e-05	5.81e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—AGT—epilepsy syndrome	3.27e-05	5.8e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—RELA—epilepsy syndrome	3.26e-05	5.79e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—SLC2A1—epilepsy syndrome	3.26e-05	5.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—FGF2—epilepsy syndrome	3.25e-05	5.76e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL18—epilepsy syndrome	3.24e-05	5.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HSPB1—epilepsy syndrome	3.24e-05	5.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—OXT—epilepsy syndrome	3.24e-05	5.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CXCL2—epilepsy syndrome	3.24e-05	5.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CCL3—epilepsy syndrome	3.24e-05	5.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CRH—epilepsy syndrome	3.24e-05	5.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PLCB1—epilepsy syndrome	3.22e-05	5.72e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—HTR2A—epilepsy syndrome	3.22e-05	5.71e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—RELA—epilepsy syndrome	3.22e-05	5.71e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—TH—epilepsy syndrome	3.21e-05	5.7e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—MTOR—epilepsy syndrome	3.2e-05	5.68e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—CCR5—epilepsy syndrome	3.2e-05	5.67e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—FYN—epilepsy syndrome	3.16e-05	5.6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—MTOR—epilepsy syndrome	3.16e-05	5.6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MEF2C—epilepsy syndrome	3.14e-05	5.57e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—H2AFX—epilepsy syndrome	3.13e-05	5.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—HTR2A—epilepsy syndrome	3.13e-05	5.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—TSC2—epilepsy syndrome	3.06e-05	5.42e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—AGT—epilepsy syndrome	3.05e-05	5.42e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—AKT1—epilepsy syndrome	3.04e-05	5.39e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—YWHAZ—epilepsy syndrome	3.04e-05	5.39e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—PRKCB—epilepsy syndrome	3.02e-05	5.36e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—YWHAZ—epilepsy syndrome	3.02e-05	5.36e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TSC1—epilepsy syndrome	3.01e-05	5.34e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PTK2B—epilepsy syndrome	3.01e-05	5.34e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—HES1—epilepsy syndrome	3e-05	5.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—APOE—epilepsy syndrome	2.99e-05	5.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—NR3C1—epilepsy syndrome	2.97e-05	5.27e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—AGT—epilepsy syndrome	2.97e-05	5.27e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—MTOR—epilepsy syndrome	2.95e-05	5.24e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—IL1B—epilepsy syndrome	2.95e-05	5.23e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CCR2—epilepsy syndrome	2.93e-05	5.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—SST—epilepsy syndrome	2.93e-05	5.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—KDR—epilepsy syndrome	2.93e-05	5.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—NTRK2—epilepsy syndrome	2.93e-05	5.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—PTGS2—epilepsy syndrome	2.93e-05	5.19e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism of RNA—AKT1—epilepsy syndrome	2.92e-05	5.18e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—FYN—epilepsy syndrome	2.92e-05	5.17e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—H2AFX—epilepsy syndrome	2.91e-05	5.15e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—DUSP6—epilepsy syndrome	2.91e-05	5.15e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—ADRA2A—epilepsy syndrome	2.87e-05	5.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—JUN—epilepsy syndrome	2.86e-05	5.07e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PLAT—epilepsy syndrome	2.86e-05	5.07e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PRKCB—epilepsy syndrome	2.82e-05	5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—JUN—epilepsy syndrome	2.82e-05	5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—IL6ST—epilepsy syndrome	2.81e-05	4.98e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—SRC—epilepsy syndrome	2.81e-05	4.98e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—YWHAZ—epilepsy syndrome	2.8e-05	4.97e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—BDKRB2—epilepsy syndrome	2.76e-05	4.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CXCL12—epilepsy syndrome	2.76e-05	4.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—AKT1—epilepsy syndrome	2.75e-05	4.89e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—POMC—epilepsy syndrome	2.75e-05	4.88e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—PRKCB—epilepsy syndrome	2.74e-05	4.87e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—AKT1—epilepsy syndrome	2.74e-05	4.85e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—VEGFA—epilepsy syndrome	2.74e-05	4.85e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—IL6ST—epilepsy syndrome	2.73e-05	4.85e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—TSC2—epilepsy syndrome	2.72e-05	4.82e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CRP—epilepsy syndrome	2.72e-05	4.82e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—JUNB—epilepsy syndrome	2.7e-05	4.8e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CNR1—epilepsy syndrome	2.7e-05	4.8e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CCR5—epilepsy syndrome	2.7e-05	4.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PLCB1—epilepsy syndrome	2.69e-05	4.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—HMOX1—epilepsy syndrome	2.68e-05	4.75e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—CAT—epilepsy syndrome	2.64e-05	4.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HTR7—epilepsy syndrome	2.64e-05	4.68e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ABCB1—epilepsy syndrome	2.57e-05	4.56e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—POMC—epilepsy syndrome	2.57e-05	4.56e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—SRC—epilepsy syndrome	2.56e-05	4.55e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HBEGF—epilepsy syndrome	2.56e-05	4.54e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by Wnt—AKT1—epilepsy syndrome	2.54e-05	4.5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—SRC—epilepsy syndrome	2.53e-05	4.48e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—AKT3—epilepsy syndrome	2.51e-05	4.46e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CCL2—epilepsy syndrome	2.51e-05	4.46e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—TSC2—epilepsy syndrome	2.51e-05	4.45e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—PRKCB—epilepsy syndrome	2.51e-05	4.45e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—POMC—epilepsy syndrome	2.5e-05	4.43e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL6ST—epilepsy syndrome	2.5e-05	4.43e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—ADAM10—epilepsy syndrome	2.46e-05	4.36e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—APOE—epilepsy syndrome	2.45e-05	4.35e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—CCL2—epilepsy syndrome	2.44e-05	4.34e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—GPX1—epilepsy syndrome	2.39e-05	4.24e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—SRC—epilepsy syndrome	2.37e-05	4.2e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—S100B—epilepsy syndrome	2.32e-05	4.12e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—IL6ST—epilepsy syndrome	2.3e-05	4.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—SOCS3—epilepsy syndrome	2.3e-05	4.08e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CDC42—epilepsy syndrome	2.29e-05	4.07e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—FOS—epilepsy syndrome	2.29e-05	4.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—NOS2—epilepsy syndrome	2.29e-05	4.06e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—FGF2—epilepsy syndrome	2.27e-05	4.03e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—CASP8—epilepsy syndrome	2.23e-05	3.96e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—AVP—epilepsy syndrome	2.22e-05	3.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—RELA—epilepsy syndrome	2.11e-05	3.74e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HES1—epilepsy syndrome	2.1e-05	3.73e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—AGT—epilepsy syndrome	2.1e-05	3.72e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MTOR—epilepsy syndrome	2.07e-05	3.67e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—APOE—epilepsy syndrome	2.05e-05	3.64e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FYN—epilepsy syndrome	2.04e-05	3.62e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—H2AFX—epilepsy syndrome	2.04e-05	3.61e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MEF2C—epilepsy syndrome	2.03e-05	3.6e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—FGF2—epilepsy syndrome	2.02e-05	3.58e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—YWHAZ—epilepsy syndrome	1.96e-05	3.48e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—NGF—epilepsy syndrome	1.94e-05	3.44e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—GPCR downstream signaling—AKT1—epilepsy syndrome	1.92e-05	3.41e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—BCL2—epilepsy syndrome	1.92e-05	3.4e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—CASP3—epilepsy syndrome	1.9e-05	3.38e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CCR5—epilepsy syndrome	1.89e-05	3.35e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—RELA—epilepsy syndrome	1.87e-05	3.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—FGF2—epilepsy syndrome	1.86e-05	3.31e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HTR2A—epilepsy syndrome	1.85e-05	3.28e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—JUN—epilepsy syndrome	1.85e-05	3.28e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—MTOR—epilepsy syndrome	1.84e-05	3.26e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MMP9—epilepsy syndrome	1.8e-05	3.19e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—POMC—epilepsy syndrome	1.77e-05	3.13e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TSC2—epilepsy syndrome	1.76e-05	3.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—AGT—epilepsy syndrome	1.75e-05	3.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—AKT1—epilepsy syndrome	1.75e-05	3.1e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—AKT1—epilepsy syndrome	1.74e-05	3.09e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—APOE—epilepsy syndrome	1.72e-05	3.05e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—MTOR—epilepsy syndrome	1.7e-05	3.01e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL1B—epilepsy syndrome	1.69e-05	3e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—KDR—epilepsy syndrome	1.68e-05	2.99e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PTGS2—epilepsy syndrome	1.68e-05	2.98e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—SRC—epilepsy syndrome	1.66e-05	2.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—JUN—epilepsy syndrome	1.64e-05	2.91e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PRKCB—epilepsy syndrome	1.62e-05	2.87e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—VEGFA—epilepsy syndrome	1.61e-05	2.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IL6ST—epilepsy syndrome	1.61e-05	2.86e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ALB—epilepsy syndrome	1.61e-05	2.85e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—AKT1—epilepsy syndrome	1.59e-05	2.83e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gene Expression—AKT1—epilepsy syndrome	1.58e-05	2.81e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—AKT1—epilepsy syndrome	1.57e-05	2.79e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—POMC—epilepsy syndrome	1.48e-05	2.62e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—SRC—epilepsy syndrome	1.47e-05	2.61e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—AKT1—epilepsy syndrome	1.47e-05	2.61e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CCL2—epilepsy syndrome	1.44e-05	2.56e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PTGS2—epilepsy syndrome	1.41e-05	2.5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—SRC—epilepsy syndrome	1.36e-05	2.41e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FGF2—epilepsy syndrome	1.31e-05	2.32e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—RELA—epilepsy syndrome	1.21e-05	2.15e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MTOR—epilepsy syndrome	1.19e-05	2.11e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—AKT1—epilepsy syndrome	1.1e-05	1.96e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—CASP3—epilepsy syndrome	1.09e-05	1.94e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—JUN—epilepsy syndrome	1.06e-05	1.88e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MMP9—epilepsy syndrome	1.03e-05	1.83e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—AKT1—epilepsy syndrome	1.03e-05	1.83e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—AKT1—epilepsy syndrome	1e-05	1.78e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—SRC—epilepsy syndrome	9.52e-06	1.69e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—VEGFA—epilepsy syndrome	9.27e-06	1.64e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—AKT1—epilepsy syndrome	9.15e-06	1.62e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—AKT1—epilepsy syndrome	9.1e-06	1.61e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—AKT1—epilepsy syndrome	8.45e-06	1.5e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—AKT1—epilepsy syndrome	7.08e-06	1.26e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—AKT1—epilepsy syndrome	5.92e-06	1.05e-05	CbGpPWpGaD
